|
WO2021041246A1
|
|
Poziotinib combination with vegfr2 inhibitors and methods of use thereof
|
|
US2021008166A1
|
|
Novel methods of treating neutorpenia using g-csf protein complex
|
|
WO2020243755A1
|
|
Methods of treatment using g-csf protein complex
|
|
WO2020061470A1
|
|
Novel quinazoline egfr inhibitors
|
|
CA3098204A1
|
|
Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
|
|
AU2019292184A1
|
|
Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
|
|
AR113451A1
|
|
INHIBITORS OF TYROSINE KINASES FROM THE FAMILY OF EGFR MUTANTS
|
|
TW201717913A
|
|
A ready-to-use formulation for vincristine sulfate liposome injection
|
|
AU2016277929A1
|
|
Combination therapy using belinostat and pralatrexate to treat lymphoma
|
|
US2014161702A1
|
|
Rare earth metal compounds, methods of making, and methods of using the same
|
|
KR20150108350A
|
|
Improved method for the preparation of liposome encapsulated vincristine for therapeutic use
|
|
US2014073680A1
|
|
Bladder cancer treatment and methods
|
|
WO2014025807A1
|
|
Pharmaceutical compositions comprising l-leucovorin
|
|
US2013338079A1
|
|
Treatment of primary and metastatic carcinoma
|
|
WO2013166318A1
|
|
Combination therapy for treating bladder cancer
|
|
WO2012135856A2
|
|
Very low dose vinorelbine for treatment of cancer
|
|
AU2011323060A1
|
|
Safely preparing and administering drug substances
|
|
AU2011252983B2
|
|
Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
|
|
TW201236680A
|
|
Thioxanthone-based autophagy inhibitor therapies to treat cancer
|
|
MX2012010212A
|
|
Thioxanthone-based autophagy inhibitor therapies to treat cancer.
|
